Binds Specifically-identified Amino Acid Sequence Patents (Class 530/387.9)
-
Publication number: 20140212888Abstract: A method has been developed to efficiently proliferate and culture a CTL specific to WT1 peptides under limiting dilution conditions. Utilizing this method, CTLs capable of recognizing both a state where a wildtype WT1 specific peptide is presented by HLA-A*24:02 and a state where a mutant WT1 specific peptide is presented by HLA-A*24:02 have been successfully obtained.Type: ApplicationFiled: August 28, 2013Publication date: July 31, 2014Applicant: Medical & Biological Laboratories Co., Ltd.Inventors: Kazue WATANABE, Shingo TOJI
-
Publication number: 20140212451Abstract: Antigenic polypeptides comprising linear immunodominant epitopes of Borrelia outer surface protein A (OspA) or Borrelia outer surface protein C (OspC) are useful as vaccines against Lyme disease, and as diagnostics for detecting Borrelia infections. The OspA and OspC antigenic polypeptides typically comprise a plurality of peptides representing epitope containing regions from multiple distinct phyletic groups. The antigenic polypeptides may also include epitopes from both Borrelia OspA and Borrelia OspC.Type: ApplicationFiled: April 2, 2014Publication date: July 31, 2014Applicant: VIRGINIA COMMONWEALTH UNIVERSITYInventors: Christopher G. Earnhart, Richard T. Marconi
-
Publication number: 20140212425Abstract: Disclosed are methods and compositions of anti-B cell antibodies, preferably anti-CD22 antibodies, for diagnosis, prognosis and therapy of B-cell associated diseases, such as B-cell malignancies, autoimmune disease and immune dysfunction disease. Preferably, the antibodies induce trogocytosis of B-cell antigens, such as CD19, CD20, CD21, CD22, CD79b, CD44, CD62L, or ?7-integrin. Trogocytosis may play a significant role in determining antibody efficacy, disease responsiveness and prognosis of therapeutic intervention and trogocytosis-dependent responses may be monitored by measuring the levels of trogocytosis of one or more B-cell surface antigens induced by the bispecific antibody.Type: ApplicationFiled: April 2, 2014Publication date: July 31, 2014Applicant: IMMUNOMEDICS, INC.Inventors: Chien-Hsing Chang, David M. Goldenberg, Hans J. Hansen, Edmund A. Rossi
-
Publication number: 20140212429Abstract: This invention relates to binding members, especially antibody molecules, specific for interleukin 1 receptor 1 (IL-1R1). For example, isolated binding members specific for IL-1R1 which competes with IL-1 and IL-1Ra for binding to IL-1R1 and binds Il-1R1 with a KD of 10 pM or less when measured by Kinexa™. The binding members are useful for, inter alia, treatment of disorders mediated by IL-1R1 including rheumatoid arthritis, asthma and chronic obstructive pulmonary disease (COPD).Type: ApplicationFiled: April 16, 2014Publication date: July 31, 2014Applicant: MEDIMMUNE LIMITEDInventors: JAMIE IAIN CAMPBELL, DUNCAN JAMES COCHRANE, DONNA KIRSTY FINCH, MARIA ANASTASIA TERESA GROVES, DAVID CHRISTOPHER LOWE, SIMON CHARLES CRUWYS
-
Publication number: 20140212481Abstract: The present invention relates to immunogenic compositions and peptides comprising residues 4-10 (FRHDSGY) of the amyloid peptide Abeta42. The invention further relates to antibodies that bind to the Abeta(4-10) antigenic determinant. The invention provides methods for treating Alzheimer's disease and for reducing the amyloid load in Alzheimers patients. The invention also relates to methods for designing small molecule inhibitors of amyloid deposition.Type: ApplicationFiled: April 7, 2014Publication date: July 31, 2014Inventors: Peter H. St. George-Hyslop, JoAnne McLaurin
-
Publication number: 20140212447Abstract: The present invention describes subunit vaccines containing Gn and Gc glycoproteins of the Rift Valley Fever Virus, including nucleic acids encoding such glycoproteins, host cells, vectors, and immunoreagents generated with the glycoproteins, methods of vaccination, methods of diagnosis, and kits.Type: ApplicationFiled: January 28, 2014Publication date: July 31, 2014Applicants: The United States Government as represented by the Secretary of Agriculture, KANSAS STATE UNIVERSITY RESEARCH FOUNDATIONInventors: Juergen A. Richt, Bonto Faburay, William Wilson
-
Patent number: 8791243Abstract: Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.Type: GrantFiled: December 29, 2008Date of Patent: July 29, 2014Assignee: Onclave Therapeutics LimitedInventors: Dale B. Schenk, Peter A. Seubert, Jonathan Wall, Jose Saldanha
-
Publication number: 20140206102Abstract: This document provides methods and materials for detecting C9ORF72 hexanucleotide (GGGGCC) (SEQ ID NO: 3) repeat expansion positive (C9+) frontotemporal lobar degeneration or C9+ amyotrophic lateral sclerosis. For example, methods and materials related to using anti-(GP)8 (SEQ ID NO: 2) antibodies to identify mammals (e.g., humans) having C9+ FTLD or C9+ ALS are provided.Type: ApplicationFiled: January 23, 2014Publication date: July 24, 2014Inventors: Leonard Petrucelli, Peter E. Ash, Tania Gendron
-
Publication number: 20140205606Abstract: The present invention relates to antibodies that specifically bind to the human c-Met receptor protein and that act as strict antagonists of hepatocyte growth factor (HGF)-mediated activation of the c-Met receptor and also inhibit HGF-independent activation of the human c-Met protein.Type: ApplicationFiled: December 6, 2013Publication date: July 24, 2014Applicant: ARGEN-X B.V.Inventors: Anna HULTBERG, Michael SAUNDERS, Johannes DE HAARD, Els FESTJENS, Natalie DE JONGE, Paolo Michieli, Christina Basilico, Torsten Dreier
-
Publication number: 20140206018Abstract: The present invention relates to antibodies that immunospecifically bind to FAS and certain FAS related proteins. The invention encompasses human and humanized forms of the antibodies and their use in treating cancers and other proliferative disorders. The invention also relates to FAS-derived peptides useful for preparing the antibodies. Methods and compositions for detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other proliferative disorders using the present antibodies also are disclosed.Type: ApplicationFiled: February 25, 2014Publication date: July 24, 2014Applicant: Nuclea Biotechnologies, Inc.Inventor: Patrick J. Muraca
-
Publication number: 20140205607Abstract: Antibody VRC01 represents a human immunoglobulin that neutralizes—˜90% of diverse HIV-1 isolates. To understand how such broadly neutralizing HIV-1 antibodies develop and recognize the viral envelope, we used X-ray crystallography and 454 pyrosequencing to characterize additional antibodies from HIV-1-infected individuals. Crystal structures revealed a convergent mode of binding of different antibodies to the same CD4-binding-site epitope. Antibody recognition was achieved through the evolution of complementary contact domains that were generated in diverse ways. Phylogenetic analysis of expressed heavy and light chains determined by deep sequencing revealed a common pathway of antibody heavy chain maturation confined to IGHV1-2*02 lineage that could pair with different light chains.Type: ApplicationFiled: March 23, 2012Publication date: July 24, 2014Applicants: DUKE UNIVERSITY, and Human ServicesInventors: John R. Mascola, Gary Nabel, Barton F. Haynes, Xueling Wu, Thomas B. Kepler, Peter Kwong
-
Publication number: 20140206556Abstract: The present invention provides a new class of peptides related to rapid replication and high human mortality, and their use in diagnosing, preventing and treating disease including vaccines and therapeutics for emerging viral diseases and methods of identifying the new class of peptides and related structures.Type: ApplicationFiled: June 19, 2013Publication date: July 24, 2014Inventors: Samuel Bogoch, Elenore S. Bogoch, Ann-Elenore Bogoch Borsanyi, Samuel Winston Bogoch
-
Patent number: 8785602Abstract: The present invention provides methods and compositions useful in the treatment or prevention of Chlamydia infections and cancer. The methods and compositions inhibit the entry of Chlamydia into a host cell expressing EMP2 by interfering with the interaction between the Chlamydia and EMP2. The methods and compositions target cancers which express or overexpress EMP2 nucleic acids and polypeptides by targeting EMP2.Type: GrantFiled: October 28, 2013Date of Patent: July 22, 2014Assignee: The Regents of the University of CaliforniaInventors: Jonathan Braun, Lynn K. Gordon, Kaori Shimazaki Dadgostar, Madhuri Wadehra, Kathleen A. Kelly, Anna M. Wu
-
Patent number: 8784830Abstract: In order to provide an effective vaccine against infection with Propionibacterium acnes, the present invention provides a peptide which is a peptide consisting of a specific amino acid sequence or a peptide consisting of an amino acid sequence derived from the specific amino acid sequence by deletion, substitution, insertion, or addition of one or more amino acids, the peptide suppressing, by immune response, inflammation caused by infection with Propionibacterium acnes.Type: GrantFiled: May 23, 2011Date of Patent: July 22, 2014Inventors: Kenichiro Hasumi, Mikio Kuraya
-
Patent number: 8784814Abstract: The invention provides an isolated protein which is a member of the TNF ligand superfamily and comprises: i) a polypeptide having the amino acid sequence of figure (1); or ii) a variant of the polypeptide of i).Type: GrantFiled: June 28, 2012Date of Patent: July 22, 2014Assignee: Glaxo Group LimitedInventors: Stuart Neville Farrow, Allard Kaptein, Jeremy David Alistair Kitson, Alison J. Winder
-
Patent number: 8785605Abstract: The present invention relates to target binding members (e.g., antibodies) that bind a specified epitope of human IL-25. The invention also relates to target binding members (e.g., antibodies) that comprise one or more humanized antibody VL domain sequences and bind IL-25. The invention further relates to compositions comprising target binding members (e.g., antibodies) that bind IL-25, methods of producing such target binding members, and uses of such target binding members for the treatment or prevention of diseases and conditions (e.g., asthma, inflammatory bowel disease).Type: GrantFiled: March 30, 2011Date of Patent: July 22, 2014Assignee: Janssen Biotech, Inc.Inventors: Juan Carlos Almagro, Patrick Branigan, Colleen Kane, William Strohl, Susann Taudte, Mark Tornetta, John Wheeler
-
Patent number: 8784828Abstract: The novel omp-1 gene cluster encoding twenty one Ehrlichia ewingii (EE) proteins was isolated and sequenced completely. This invention relates to isolated E. ewingii (EE) polypeptides, isolated polynucleotides encoding EE polypeptides, probes, primers, isolated antibodies and methods of their production, immunogenic compositions and vaccines, as well as methods of using the EE polypeptides, antibodies, probes, and primers for the purpose of diagnosis, therapy and production of vaccines against E. ewingii.Type: GrantFiled: May 5, 2008Date of Patent: July 22, 2014Assignee: The Ohio State University Research FoundationInventor: Yasuko Rikihisa
-
Publication number: 20140199313Abstract: The present invention relates to a process for the production of the fine chemical in a microorganism, a plant cell, a plant, a plant tissue or in one or more parts thereof, preferably in plastids. The invention furthermore relates to nucleic acid molecules, polypeptides, nucleic acid constructs, vectors, antibodies, host cells, plant tissue, propagation material, harvested material, plants, microorganisms as well as agricultural compositions and to their use.Type: ApplicationFiled: February 28, 2006Publication date: July 17, 2014Applicant: Metanomics GmbHInventors: Gunnar Plesch, Piotr Puzio, Astrid Blau, Ralf Looser, Birgit Wendel, Beate Kamlage, Micheal Manfred Herold, Florian Schauwecker
-
Publication number: 20140199314Abstract: Modulation of iron homeostasis by regulating BMP-6 activity is provided. Methods of using BMP-6 and BMP-6 protein-specific reagents, such as antibodies, for altering serum iron levels in humans are provided. Such antibodies are useful in pharmaceutical compositions for the prevention and treatment of anemia and anemia of inflammation.Type: ApplicationFiled: March 15, 2013Publication date: July 17, 2014Applicant: The General Hospital CorporationInventors: Herbert Y. Lin, Jodie Babitt
-
Publication number: 20140199311Abstract: This invention provides an antibody targeting a cancer antigenic protein specifically expressed on the surface of cancer cells and use thereof as a therapeutic and/or preventive agent for cancer. More specifically, the present invention provides an antibody, or a fragment thereof which has immunological reactivity with a CAPRIN-1 protein, the antibody comprising a heavy chain variable region comprising complementarity determining regions of SEQ ID NOs: 5, 6, and 7 and a light chain variable region comprising complementarity determining regions of SEQ ID NOs: 9, 10, and 11, and a pharmaceutical composition for treatment and/or prevention of cancer, comprising the same as an active ingredient.Type: ApplicationFiled: August 3, 2012Publication date: July 17, 2014Applicant: TORAY INDUSTRIES, INC.Inventors: Shinichi Kobayashi, Fumiyoshi Okano, Takanori Saito
-
Publication number: 20140199318Abstract: The invention relates to means for detecting, binding, removing and/or neutralising agonistic antibodies associated with dementia, preferably Alzheimer's disease or vascular dementia.Type: ApplicationFiled: July 13, 2012Publication date: July 17, 2014Applicants: MAX-DEL-BRUCK-CENTRUM FUR MOLEKULARE MEDIZIN, E.R.D.E.-AAK-DIAGNOSTIK GMBHInventors: Marion Bimmler, Peter Karczewski, Petra Hempel
-
Publication number: 20140199310Abstract: We disclose agents that inhibit the expression of NETO-2 which has elevated expression in cancer stem cells; the use of NETO-2 as a diagnostic or prognostic marker of tumour initiation; the use NETO-2 polypeptides in the identification of agents that inhibit activity; and including antibodies that bind NETO-2 and vaccines comprising NETO-2 polypeptides.Type: ApplicationFiled: March 27, 2014Publication date: July 17, 2014Applicant: University of YorkInventors: Richard Birnie, Norman Maitland
-
Publication number: 20140199306Abstract: The present invention relates to compositions and methods for the inhibition of EPO. The invention provides antibodies and antigen binding fragments thereof that bind to EPO and are able to inhibit EPO-dependent cell proliferation and/or EPO-dependent cell signaling.Type: ApplicationFiled: December 3, 2013Publication date: July 17, 2014Applicant: NOVARTIS AGInventors: Joy GHOSH, Mark Anthony RUTZ, Katrin Ulrike TISSOT-DAGUETTE, Igor SPLAWSKI, Michael ROGUSKA
-
Publication number: 20140199317Abstract: The disclosure provides, among other aspects, neutralizing antibodies and portions thereof that bind to ActRIIA and uses for same.Type: ApplicationFiled: January 24, 2014Publication date: July 17, 2014Applicant: ACCELERON PHARMA, INC.Inventors: Jasbir Seehra, Erik Martinez-Hackert
-
Publication number: 20140199315Abstract: Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination (Negative Regulator). Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies.Type: ApplicationFiled: November 12, 2013Publication date: July 17, 2014Applicant: Biogen Idec MA Inc.Inventors: Sha MI, R. Blake Pepinsky, Zhaohui Shao, Christilyn Graff
-
Publication number: 20140200187Abstract: The present invention refers to protein kinase inhibitors and more specifically to inhibitors of the protein kinase c-Jun amino terminal kinase. Additionally, the present invention provides JNK inhibitor sequences, chimeric peptides, nucleic acids encoding same as well as pharmaceutical compositions for treating pathophysiologies associated with JNK signaling.Type: ApplicationFiled: December 31, 2013Publication date: July 17, 2014Applicant: XIGEN INFLAMMATION LTD.Inventor: Christophe Bonny
-
Publication number: 20140199361Abstract: The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use.Type: ApplicationFiled: July 20, 2012Publication date: July 17, 2014Inventors: Con Panousis, Veronika Rayzman, Andrew Nash, Michael Wilson, Stefan Schmidbauer, Marc Nolte
-
Publication number: 20140199309Abstract: The invention provides methods for treating HIF-1?-overexpressing human tumors, inhibiting HIF-1?-overexpressing tumor invasion and preventing tumor metastasis, and/or promoting tumor prophylaxis, using various types of inhibitors against the Hsp90? from the tumors.Type: ApplicationFiled: March 25, 2014Publication date: July 17, 2014Applicant: University of Southern CaliforniaInventors: Wei Li, David T. Woodley, Mei Chen
-
Patent number: 8779099Abstract: Methods and compositions for using the MHC class II invariant chain polypeptide, Ii (also known as CD74), as a receptor for macrophage migration inhibitory factor (MIF), are disclosed. These include methods and compositions for using this receptor, as well as agonists and antagonists of MIF which bind to this receptor, or which otherwise modulate the interaction of MIF with CD74 or the consequences of such interaction, in treatment of conditions characterized by locally or systemically altered MIF levels, particularly inflammatory conditions and cancer.Type: GrantFiled: June 14, 2011Date of Patent: July 15, 2014Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Richard J. Bucala, Lin Leng, Christine N. Metz
-
Patent number: 8779104Abstract: The present invention provides methods and compositions useful in the treatment or prevention of Chlamydia infections and cancer. The methods and compositions inhibit the entry of Chlamydia into a host cell expressing EMP2 by interfering with the interaction between the Chlamydia and EMP2. The methods and compositions target cancers which express or overexpress EMP2 nucleic acids and polypeptides by targeting EMP2.Type: GrantFiled: August 21, 2013Date of Patent: July 15, 2014Assignee: The Regents of the University of CaliforniaInventors: Jonathan Braun, Lynn K. Gordon, Kaori Shimazaki Dadgostar, Madhuri Wadehra, Kathleen A. Kelly, Anna M. Wu
-
Patent number: 8778885Abstract: The invention provides a method for treating a medical condition, disease, or disorder mediated by a misfolded form of superoxide dismutase (SOD) in a subject in need of treatment. The method optionally comprises administering to the subject a composition comprising a pharmaceutically acceptable vehicle and an agent selected from (1) an exogenous antibody or fragment thereof that binds selectively to the misfolded form of SOD, and/or (2) an immunogen that elicits production of an endogenous antibody that binds selectively to the misfolded form of SOD, and/or (3) a nucleic acid sequence encoding (1) or (2). In certain embodiments, the invention provides methods of treating diseases such as Alzheimer's Disease, Parkinson's Disease or amyotrophic lateral sclerosis using amyotrophic disease-specific epitopes, and compositions including these epitopes. The invention also provides antibodies that bind to monomeric or misfolded SOD1, and not on the molecular surface of native homodimeric SOD1.Type: GrantFiled: June 8, 2011Date of Patent: July 15, 2014Assignee: Amorfix Life Sciences Ltd.Inventors: Neil R. Cashman, Avijit Chakrabartty, Rishi Rakhit, Joachim Bernhard Ostermann
-
Patent number: 8778699Abstract: A method for determining the amount of NT-proBNP in blood samples from animals. The method includes detecting degradation products of NT-proBNP by various methods, including using antibodies, kits and device.Type: GrantFiled: August 4, 2011Date of Patent: July 15, 2014Assignee: Idexx Laboratories, Inc.Inventors: Mahalakshmi Yerramilli, Michael Atkinson, Murthy V. S. N. Yerramilli
-
Patent number: 8778346Abstract: The present invention relates to anti-IL-23p19 binding compounds, in particular new humanized anti-IL-23p19 antibodies and therapeutic and diagnostic methods and compositions for using the same.Type: GrantFiled: November 2, 2011Date of Patent: July 15, 2014Assignee: Boehringer Ingelheim International GmbHInventors: Rachel Rebecca Barrett, Keith Canada, Katrina Mary Catron, Robert Copenhaver, Lee Edward Frego, Ernest Lee Raymond, Sanjaya Singh, Xiangyang Zhu
-
Publication number: 20140193332Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of inflammatory bowel diseases in mammals and to methods of using those compositions of matter for the same.Type: ApplicationFiled: November 4, 2013Publication date: July 10, 2014Applicant: GENENTECH, INC.Inventors: Audrey Goddard, Austin L. Gurney
-
Publication number: 20140194299Abstract: Compositions, methods and related uses are provided relating to cleaving modified DNA. For example, a set of DNA fragments obtainable by enzymatic cleavage of a large DNA is described where at least 50% are similarly sized and have a centrally positioned modified nucleotide. In addition, an enzyme preparation is provided that includes one or more enzymes that recognize a modified nucleotide in a DNA and cleave the DNA at a site that is at a non-random distance from the modified nucleotide. The one or more enzymes are further characterized by an N-terminal conserved domain with greater than 90% amino acid sequence homology to WXD(X)10YXGD. The related uses include creating a methylome, methods of purifying DNA fragments containing a modified nucleotide and diagnostic applications.Type: ApplicationFiled: January 30, 2014Publication date: July 10, 2014Applicant: New England Biolabs, Inc.Inventors: YU ZHENG, RICHARD J. ROBERTS
-
Publication number: 20140194599Abstract: Anti-human IL20 monoclonal antibodies that can reduce IL20 mediated activation of both IL20R1/IL20R2 and IL22R1/IL20R2 receptor complexes in one or more species, including humans, are described, as well as antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules designed or derived from such antibodies, and methods or producing such antibodies or other antigen-binding molecules. Such antibodies or other antigen-binding molecules can be used for treating various diseases and disorders, including autoimmune or inflammatory diseases or disorders.Type: ApplicationFiled: August 21, 2013Publication date: July 10, 2014Applicant: NOVO NORDISK A/SInventors: Jesper Pass, Soeren Oestergaard, Jes Thorn Clausen
-
Publication number: 20140193418Abstract: Herein is reported an antibody that specifically binds to human EPO receptor, wherein the antibody binds to EPO receptor fragment LPGPGGSVDIV (SEQ ID NO: 01) but that does not specifically bind to a protein obtainable from human endothelial cells that has a molecular weight of about 66 kD.Type: ApplicationFiled: December 5, 2013Publication date: July 10, 2014Applicant: HOFFMANN-LA ROCHE INC.Inventors: Michael Jarsch, Olaf Mundigl
-
Publication number: 20140193829Abstract: The present invention relates to monoclonal antibodies against PrPSc protein. The anti-PrPSc mAbs produced of this invention can specifically detect PrPSc protein from normal mouse brain homogenates without pre-treatment with protease K, which may be used in developing a diagnostic method and kit for prion disease with high specificity and sensitivity.Type: ApplicationFiled: December 24, 2013Publication date: July 10, 2014Applicant: NATIONAL YANG-MING UNIVERSITYInventors: Yi-Ming Arthur CHEN, Szu-Wei HUANG, Ying-YU LIN
-
Publication number: 20140193402Abstract: The present invention provides antibodies that bind to platelet derived growth factor receptor beta (PDGFR-beta) and methods of using the same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human PDGFR-beta with high affinity. The antibodies of the invention are useful for the treatment of diseases and disorders associated with PDGFR-beta signaling and/or PDGFR-beta cellular expression, such as ocular diseases, fibrotic diseases, vascular diseases and cancer.Type: ApplicationFiled: January 7, 2014Publication date: July 10, 2014Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: Stanley J. WIEGAND, Ivan B. LOBOV
-
Publication number: 20140193397Abstract: The invention provides methods for identifying patient who may benefit from treatment with an anti-cancer therapy comprising a VEGF antagonist. The invention also provides methods for monitoring a patients' response to the anti-cancer therapy. The invention also provides kits and articles of manufacture for use in the methods.Type: ApplicationFiled: March 13, 2013Publication date: July 10, 2014Applicants: GENENTECH. INC., HOFFMANN-LA ROCHE INC.Inventors: Hoffmann-La Roche Inc., Genentech. Inc.
-
Publication number: 20140193403Abstract: The present invention relates neutralising epitopes of IL-17A and IL-17F and antibodies which bind those epitopes. The present invention also relates to the therapeutic uses of the antibody molecules and methods for producing them.Type: ApplicationFiled: February 5, 2014Publication date: July 10, 2014Applicant: UCB Pharma S.A.Inventors: Thomas Allen Ceska, Alistar James Henry, Jiye Shi
-
Publication number: 20140193399Abstract: The present invention is related to antibodies directed to the antigen CD3 and uses of such antibodies. In particular, the present invention provides fully human monoclonal antibodies directed to CD3. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.Type: ApplicationFiled: October 8, 2013Publication date: July 10, 2014Inventors: Bernard Mach, Yann Dean, Marie Kosco-Vilbois, Greg Elson, Nicolas Fischer, Olivier Leger
-
Publication number: 20140194598Abstract: The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.Type: ApplicationFiled: February 12, 2014Publication date: July 10, 2014Inventors: Glen Eugene Mikesell, Han Chang, Joshua N. Finger, Guchen Yang, Robert James Peach, Henry Shen
-
Publication number: 20140193432Abstract: The present invention provides: antibodies specifically reacting against hDlk-1 and having anti-tumor activity in vivo (anti-hDlk-1 antibodies, and in particular, humanized anti-hDlk-1 antibodies); fragments of the antibodies; hybridomas that produce the antibodies; a complex of the antibody or antibody fragment and an agent; a pharmaceutical composition, a tumor therapeutic agent, a tumor diagnostic agent and an agent for inducing apoptosis in tumor cells, each of which comprises the aforementioned antibody or the like; a method for treating tumor, a method for detecting tumor, a method for inducing apoptosis in tumor cells, a kit for detecting and/or diagnosing tumor and a kit for inducing apoptosis in tumor cells, each of which comprises the use of the aforementioned antibody or the like; etc.Type: ApplicationFiled: October 3, 2013Publication date: July 10, 2014Applicant: LIVTECH, INC.Inventors: Koji NAKAMURA, Hiroyuki YANAI, Toru KANKE, Naoya TSURUSHITA, Shankar KUMAR
-
Publication number: 20140193417Abstract: The present disclosure relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.Type: ApplicationFiled: September 26, 2013Publication date: July 10, 2014Inventors: Gerd Ritter, Beatrice Yin, Anne Murray, George Mark, Lloyd J. Old, Kenneth Lloyd, Serhiy Souchelnytskiy, Ivan Gout, Valeriy Filonenko, Ramziya Kiyamova
-
Publication number: 20140193421Abstract: An object of the present invention is to provide a monoclonal antibody binding to human XCR1, wherein the antibody binds to linear or discontinuous epitopes which comprise at least three amino acids selected from the group consisting of the 8th, 11th, 12th, 13th, 14th, 16th, 17th, 22nd, 23rd, 176th, and 177th amino acids in the amino acid sequence of SEQ ID NO: 91.Type: ApplicationFiled: August 30, 2012Publication date: July 10, 2014Applicant: EISAI R&D MANAGEMENT CO., LTD.Inventors: Yoshimasa Sakamoto, Miyuki Nishimura, Tetsu Kawano, Yukihisa Sawa, Toshio Imai
-
Publication number: 20140193419Abstract: Methods and compositions for diagnosing and treating diseases, particularly cancer, associated with differential expression of cancer-associated targets (CAT) in disease cells compared to healthy cells are provided. Also provided are antagonists and agonists of CAT, and methods for screening agents that modulate CAT level or activity in vivo or in vitro.Type: ApplicationFiled: December 6, 2013Publication date: July 10, 2014Applicant: CELERA CORPORATIONInventors: Steve RUBEN, Karen VAN ORDEN, Bruno DOMON, Candy LEE, Tao HE, Mehdi MESRI, Elizabeth JOSELOFF, Katherine MCKINNON, Paul MOORE, Charles BIRSE
-
Publication number: 20140193420Abstract: Disclosed is a monoclonal antibody binding to an ITM2A protein. This antibody is useful in the diagnosis, prevention, and treatment of cancer such as Ewing's sarcoma, T cell leukemia, T cell lymphoma, acute myeloid leukemia, B cell tumor, and multiple myeloma. The present invention also provides a pharmaceutical composition, a cell growth inhibitor, and an anticancer agent containing the antibody as an active ingredient, and a method for treating cancer, a method for predicting the efficacy of cancer treatment, and a method for determining the presence of cancer in a test subject using the antibody.Type: ApplicationFiled: April 18, 2012Publication date: July 10, 2014Applicants: CHUGAI SEIYAKU KABUSHIKI KAISHA, THE UNIVERSITY OF TOKYOInventors: Hiroyuki Aburatani, Shumpei Ishikawa, Shigeto Kawai
-
Patent number: 8775090Abstract: Provided herein are crystalline forms of a human IgG Fc variant comprising triple-mutation M252Y/S254T/T256E that provides for increased binding affinity to human neonatal Fc receptor, methods of obtaining such crystals and high-resolution X-ray diffraction structures and atomic structure coordinates. Also provided are machine readable media embedded with the three-dimensional atomic structure coordinates of the human IgG Fc variant and methods of using them.Type: GrantFiled: December 10, 2009Date of Patent: July 8, 2014Assignee: MedImmune, LLCInventors: Vaheh Oganesyan, William F. Dall'Acqua, Herren Wu
-
Patent number: 8771693Abstract: The present invention features methods and compositions for the generation and use of conformation-specific anti-bodies or fragments thereof.Type: GrantFiled: October 26, 2010Date of Patent: July 8, 2014Assignee: Beth Israel Deaconess Medical Center, Inc.Inventors: Kun Ping Lu, Xiao Zhen Zhou